dalteparin has been researched along with Foot Ulcer in 3 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Foot Ulcer: Lesion on the surface of the skin of the foot, usually accompanied by inflammation. The lesion may become infected or necrotic and is frequently associated with diabetes or leprosy.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have previously reported an improved outcome of chronic diabetic foot ulcers during treatment with dalteparin." | 9.12 | Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. ( Apelqvist, J; Blombäck, M; Eliasson, B; Eriksson, JW; Fagrell, B; Hamsten, A; Jörneskog, G; Kalani, M; Silveira, A; Torffvit, O, 2007) |
| "Using a computer algorithm 284 patients with lower limb ischemia, most with pre-operative ischemic ulceration or partial gangrene, from 12 hospitals were randomised, after PABG, to 5000 IU dalteparin or placebo injections once daily for 3 months." | 9.11 | Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. ( Drott, C; Gelin, J; Groth, O; Hensäter, M; Jensen, N; Jivegård, L; Johansson, G; Konrad, P; Lindberg, B; Lindhagen, A; Lundqvist, B; Oden, A; Ortenwall, P; Smith, L; Stenberg, B; Thornell, E; Wingren, U, 2005) |
| " We have previously reported an improved outcome of chronic diabetic foot ulcers during treatment with dalteparin." | 5.12 | Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. ( Apelqvist, J; Blombäck, M; Eliasson, B; Eriksson, JW; Fagrell, B; Hamsten, A; Jörneskog, G; Kalani, M; Silveira, A; Torffvit, O, 2007) |
| "Using a computer algorithm 284 patients with lower limb ischemia, most with pre-operative ischemic ulceration or partial gangrene, from 12 hospitals were randomised, after PABG, to 5000 IU dalteparin or placebo injections once daily for 3 months." | 5.11 | Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. ( Drott, C; Gelin, J; Groth, O; Hensäter, M; Jensen, N; Jivegård, L; Johansson, G; Konrad, P; Lindberg, B; Lindhagen, A; Lundqvist, B; Oden, A; Ortenwall, P; Smith, L; Stenberg, B; Thornell, E; Wingren, U, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aragón-Sánchez, J | 1 |
| Lázaro-Martínez, JL | 1 |
| Jivegård, L | 1 |
| Drott, C | 1 |
| Gelin, J | 1 |
| Groth, O | 1 |
| Hensäter, M | 1 |
| Jensen, N | 1 |
| Johansson, G | 1 |
| Konrad, P | 1 |
| Lindberg, B | 1 |
| Lindhagen, A | 1 |
| Lundqvist, B | 1 |
| Oden, A | 1 |
| Smith, L | 1 |
| Stenberg, B | 1 |
| Thornell, E | 1 |
| Wingren, U | 1 |
| Ortenwall, P | 1 |
| Kalani, M | 1 |
| Silveira, A | 1 |
| Blombäck, M | 1 |
| Apelqvist, J | 1 |
| Eliasson, B | 1 |
| Eriksson, JW | 1 |
| Fagrell, B | 1 |
| Torffvit, O | 1 |
| Hamsten, A | 1 |
| Jörneskog, G | 1 |
2 trials available for dalteparin and Foot Ulcer
| Article | Year |
|---|---|
Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial.
Topics: Aged; Dalteparin; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Fo | 2005 |
Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers.
Topics: Aged; Dalteparin; Diabetes Mellitus; Double-Blind Method; Female; Fibrinolytic Agents; Foot Ulcer; H | 2007 |
1 other study available for dalteparin and Foot Ulcer
| Article | Year |
|---|---|
Comments on the use of bemiparin in diabetic foot ulcers.
Topics: Anticoagulants; Diabetic Foot; Foot Ulcer; Heparin, Low-Molecular-Weight; Humans | 2009 |